Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like Alzheimer's and Parkinson's.

SGD Pharma Launches Sterile Nasal Vial Platform for US Market

The two companies have entered into a licensing agreement to commercialize biosimilars in Latin America.

SteinCares and Shilpa Biologicals Collaborate on Biosimilar Access for Latin America

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a treatment for the ultra-rare disease, fibrodysplasia ossificans progressiva.

Quotient Sciences Extends Partnership with Ipsen for Manufacture of Ultra-Rare Disease Treatment

Lars Hahn is senior vice-president, Global Sales Organization, at Vetter.

Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.

Navigating Biopharma Complexity: Why Long-Term Partnerships Matter 

Katie Edgar is chief business officer at KBI Biopharma.

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before uncertainty becomes late-stage risk. 

How Innovation Is Reshaping Outsourced Development and Manufacturing 

Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development. 

Outsourcing Formulation Activities May Advance Drug Development

Andrew Mitchell is associate vice president of Business Development at BioVectra.

Videos

PharmTech spoke with Andrew Mitchell, associate vice president of Business Development at BioVectra, about which 2025 trends will continue to impact the pharma industry and how CDMOs can offer solutions.

Insights on New Modalities, Digital Integration, and Manufacturing Innovation

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. 

Lilly and CSL Partner on Clazakizumab Antibody Development

Mike Schaefers is chief commercial officer at Simtra BioPharma Solutions.

Integrated CDMO networks streamline complex drug development across advanced modalities like ADCs. 

How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs

PharmTech spoke with Katy MacLellan, Technical Team leader, Symbiosis Pharmaceutical Services Ltd., about the women in the pharmaceutical industry that inspire her.